X-Rite Incorporated and Pantone LLC, global leaders in color science and technology, announce the eXact 2, a next-generation non-contact handheld spectrophotometer designed to bring the ink, print, ...
Exact Sciences is shifting its focus towards achieving positive adjusted EBITDA as a way to signal a path to eliminate cash burn. The company's long-term prospects look interesting with a pipeline ...
See Correction/Clarification at the end of this article. Madison-based cancer screening test maker Exact Sciences Corp. expects to turn profitable in 2024, the company's chief financial officer and ...
The average one-year price target for Exact Sciences (NASDAQ:EXAS) has been revised to 103.99 / share. This is an increase of 17.84% from the prior estimate of 88.25 dated June 1, 2023. The price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback